| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $215.3M | +70.6% |
| SG&A Expense | $100.2M | +144.4% |
| Operating Income | -$315.5M | -88.7% |
| Pre-tax Income | -$299.6M | -96.9% |
| Income Tax | $1K | +0.0% |
| Net Income | -$299.6M | -96.9% |
| EPS (Basic) | -$4.66 | -69.5% |
| EPS (Diluted) | -$4.66 | -69.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $354.7M | +282.9% |
| Short-term Investments | $359.9M | -34.4% |
| Current Assets | $728.9M | +11.9% |
| Total Assets | $734.7M | +12.1% |
| Current Liabilities | $53.5M | +110.7% |
| Long-term Debt | $74.8M | +47.6% |
| Total Liabilities | $130.2M | +65.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$241.1M | -79.0% |
| Capital Expenditures | $630K | -35.2% |
| Investing Cash Flow | $194.3M | +145.7% |
| Financing Cash Flow | $308.9M | -49.1% |
| Free Cash Flow | -$241.7M | -78.2% |
| Stockholders' Equity |
| $604.5M |
| +4.7% |